In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lorantis Ltd.

Division of Celldex Therapeutics Inc.
www.lorantis.com

Latest From Lorantis Ltd.

Biotech Money, Where Art Thou?

While public biotech funding in the US in 2003 outpaced private funding by more than five to one, the smaller financing picture in Europe tells a different story.
BioPharmaceutical Europe

2004: Consolidation Year for European Biotech?

Despite investors' pleas, most observers agree there are still far too many small, sub-critical biotech firms in Europe. Yet two late-2003 deals-CeNeS' acquisition of TheraSci, and Develogen's merger with Peptor-may point to more consolidation both in public and private European biotech during 2004. And the early signs are that such deals may be driven less by sheer desperation, and more by a recognition of what both public and private investors want.
BioPharmaceutical Europe

Recent Dealmaking (01/2004)

Summarizing the month in European dealmaking.

Lorantis Ltd.

Existing drugs for immune-related conditions, such as Novartis AG's cyclosporin, tend to either suppress the system altogether (often with considerable side effects), or, like anti-inflammatory or broncho-dilatory products for asthma, treat the symptoms of the disease. This is because scientists have to date understood little of the workings of immune system tolerance, or indeed of immune system regulation more generally. The founding scientists of Lorantis Ltd. hope to have made some progress in this area. They have discovered the molecular mechanism underlying antigen-specific tolerance in animal models, potentially paving the way for a new generation of therapies that treat the causes of various immune-related diseases, rather than their symptoms.
BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Inflammation
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Celldex Therapeutics Inc.
  • Senior Management
  • Andrew Muncey, CFO
    Karl Schaffenburg , CBO
  • Contact Info
  • Lorantis Ltd.
    Phone: (44) 1223 702 500
    307 Cambridge Science Park
    Cambridge, CB4 OWG
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register